Global Markets for Enzyme Inhibitors

  • July 2012
  • -
  • BCC Research
  • -
  • 315 pages

INTRODUCTION

STUDY GOALS AND OBJECTIVES

The overall goal of this study is to provide a comprehensive understanding of the current and future characteristics of the global market for enzyme inhibitors.

This report explores present and future strategies within the market for enzyme inhibitors, which includes proton pump inhibitors (PPIs), protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, phosphodiesterase type 5 (PDE5) inhibitors, neuraminidase inhibitors, and angiotensin-converting enzyme (ACE) inhibitors. The improvements in the market and the setbacks and needs of the market are discussed in this report. The comparisons, usage, and advantages and disadvantages of different types of enzyme inhibitors are also discussed in this report.

A detailed analysis of the enzyme inhibitors industry structure has been conducted. Revenues are broken down by region. Sales figures are estimated for the five-year forecast period of this report, from 2011 to 2016.

Applications for enzyme inhibitors are also discussed in the report, with emphasis on the usage of the inhibitors in therapeutic categories and various disease sectors. The report also covers significant patents and their allotments in each category.



REASONS FOR DOING THE STUDY

Extensive research in the field of enzyme inhibitors has revealed their target-specific functionality in being able to provide therapeutic treatments for various chronic diseases. Modern industries have now begun to explore the advantages of enzyme inhibitors in their productions and processes. This has led to steady market growth for enzyme inhibitors.

Research and development (R&D) spending, along with increasing competition, patent expirations and new technologies, is directing this to a new level. Although, due to patent expirations, the overall revenue for the market has decreased slightly from 2009 to 2011, new advancements, new product launches and the changing lifestyle will cause the market to grow in the foreseeable future. This study looks at almost all the systems affected by these factors.

Acquisition strategies and collaborations by companies are also covered in this report. This study also discusses the strengths and weaknesses of each type/technology in light of the new technologies, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE

This report provides invaluable information to manufacturers and users of PPIs, protease inhibitors, reverse transcriptase inhibitors, kinase inhibitors, statins, aromatase inhibitors, PDE5 inhibitors, neuraminidase inhibitors, and ACE inhibitors. Pharmaceutical and biotechnology companies, research institutes, and physicians will find this study to be of interest.

SCOPE OF REPORT

The scope of this study encompasses enzyme inhibitors in the pharmaceutical and biotechnology industry. BCC Research analyzes each market and its applications, regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments. Emerging markets for enzyme inhibitors include countries such as India, China, Japan, Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY AND INFORMATION SOURCES

BCC conducted a comprehensive literature search, which included technical newsletters and journals. The data were collected through interviews and correspondence with technical experts manufacturing enzyme inhibitors. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease sectors industries. The data were carefully collected from various industry sources. BCC spoke with officials within the industry and consulted newsletters; company and product literature; and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, the data were compiled from current financial, trade and government sources.

ANALYST CREDENTIALS

The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master’s degree in pharmaceutical chemistry and has more than 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Dewan was awarded a Gold Medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are Reagents for Chromatography; Spectroscopy, An Enduring Market; Advanced Drug Delivery Systems: Technologies and Global Markets; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging: Global Markets; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets.

The lead consultant for this project is Dr. Kapil A. Setia, who has a doctorate in life sciences. She has a number of research publications in her credit, including her thesis on “Studies on Phenotypic Variation, Clonal Propagation and Phyto-chemistry of Tinospora cordifolia (Willd.),” which was given an award of excellence.

Table Of Contents

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
CONTRIBUTIONS OF THE STUDY AND INTENDED AUDIENCE 2
SCOPE OF REPORT 2
METHODOLOGY AND INFORMATION SOURCES 2
ANALYST CREDENTIALS 3
RELATED REPORTS 3
BCC ON-LINE SERVICES 4
DISCLAIMER 4
CHAPTER TWO: SUMMARY 5
SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF ENZYME INHIBITORS
MARKET, THROUGH 2016 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF ENZYME INHIBITORS
MARKET, 2009-2016 ($ MILLIONS) 7
CHAPTER THREE: OVERVIEW 8
DEFINITIONS 8
STRUCTURE OF ENZYMES 8
ACTIVATION ENERGY 8
SPECIFICITY 9
ENZYME SUBSTRATE INTERACTION 9
CONDITIONS OF ENZYME ACTION 9
CLASSIFICATION OF ENZYMES 10
OXIDOREDUCTASES 10
TRANSFERASES 11
HYDROLASES 11
Nucleases 12
Phosphatases 12
LYASES 12
ISOMERASES 12
LIGASES 13
REAL-LIFE APPLICATIONS OF ENZYMES 13
METABOLIC ENZYMES 14
DIGESTIVE ENZYMES 15
FOOD ENZYMES 16
NEED FOR ENZYMES IN HUMAN BODY 16
PROTEOLYTIC ENZYMES 17
LIPOLYTIC ENZYMES 17
AMYLOLYTIC ENZYMES 17
RENNIN ENZYMES 18
WHAT ARE ENZYME INHIBITORS 18
WHY ENZYME INHIBITION 18
USE OF ENZYME INHIBITORS 19
MECHANISM OF ENZYME INHIBITION 19
TYPES OF ENZYME INHIBITORS 20
MIXED INHIBITION 20
COMPETITIVE INHIBITION 20
CLASSIFICATION OF ENZYME INHIBITORS 21
TABLE 1 CLASSIFICATION OF ENZYME INHIBITORS 21
OXIDOREDUCTASE INHIBITORS 22
Aldose Reductase Inhibitors 22
Statins 22
History of Development of Statins 23
TABLE 2 HISTORY OF DEVELOPMENT OF STATINS 23
5-Alpha-Reductase Inhibitors 23
Aromatase Inhibitors 23
COX-2 Inhibitors 24
HYDROLASE INHIBITORS 24
Neuraminidase Inhibitors 24
Protease Inhibitors 25
TABLE 3 HISTORY OF DISCOVERY OF PROTEASE INHIBITORS 25
Phosphodiesterase Type 5 (PDE5) Inhibitors 26
Phosphodiesterase Type 4 (PDE4) Inhibitors 26
Angiotensin-Converting Enzyme (ACE) Inhibitors 27
TABLE 4 DEVELOPMENT OF ACE INHIBITORS 27
Proton Pump Inhibitors 28
TRANSFERASE INHIBITORS 28
Protein Kinase Inhibitors 28
Reverse Transcriptase Inhibitors 29
CHAPTER FOUR: REGULATORY ASPECTS 30
TABLE 5 NEW DRUG APPROVALS FOR ENZYME INHIBITORS, 2008-
2011 30
TABLE 5 (CONTINUED) 31
TABLE 5 (CONTINUED) 32
TABLE 5 (CONTINUED) 33
TABLE 6 NEW DRUG APPLICATIONS FOR ENZYME INHIBITORS 34
TABLE 7 SAFETY ALERTS FOR ENZYME INHIBITORS, 2008-2011 35
TABLE 7 (CONTINUED) 36
TABLE 7 (CONTINUED) 37
CHAPTER FIVE: MARKET LEADERS AND THEIR PRODUCTS FOR
ENZYME INHIBITORS 38
TABLE 8 LEADING MANUFACTURERS/SUPPLIERS OF PROTON
PUMP INHIBITORS 38
TABLE 9 LEADING MANUFACTURERS/SUPPLIERS OF PROTEASE
INHIBITORS 38
TABLE 9 (CONTINUED) 39
TABLE 10 LEADING MANUFACTURERS/SUPPLIERS OF KINASE
INHIBITORS 39
TABLE 11 LEADING MANUFACTURERS/SUPPLIERS OF STATINS 40
TABLE 12 LEADING MANUFACTURERS/SUPPLIERS OF
AROMATASE INHIBITORS 40
TABLE 13 LEADING MANUFACTURERS/SUPPLIERS OF REVERSE
TRANSCRIPTASE INHIBITORS 41
TABLE 14 LEADING MANUFACTURERS/SUPPLIERS OF PED5
INHIBITORS 42
TABLE 15 LEADING MANUFACTURERS/SUPPLIERS OF
NEURAMINIDASE INHIBITORS 42
TABLE 16 LEADING MANUFACTURERS/SUPPLIERS OF ACE
INHIBITORS 42
TABLE 16 (CONTINUED) 43
CHAPTER SIX: NEW DEVELOPMENTS 44
TABLE 17 CLINICAL TRIALS ENZYME INHIBITORS 44
TABLE 17 (CONTINUED) 45
TABLE 18 CLINICAL TRIALS OF STATINS 45
TABLE 18 (CONTINUED) 46
TABLE 19 CLINICAL TRIALS FOR AROMATASE INHIBITORS 47
TABLE 20 CLINICAL TRIALS FOR REVERSE TRANSCRIPTASE
INHIBITORS 47
TABLE 20 (CONTINUED) 48
TABLE 20 (CONTINUED) 49
TABLE 21 CLINICAL TRIALS FOR PROTEIN KINASE INHIBITORS 49
TABLE 21 (CONTINUED) 50
TABLE 21 (CONTINUED) 51
TABLE 21 (CONTINUED) 52
TABLE 21 (CONTINUED) 53
TABLE 22 CLINICAL TRIALS FOR PDE5 INHIBITORS 54
TABLE 23 CLINICAL TRIALS FOR PDE4 INHIBITORS 54
TABLE 23 (CONTINUED) 55
TABLE 24 CLINICAL TRIALS FOR PROTEASE INHIBITORS 55
TABLE 24 (CONTINUED) 56
TABLE 25 CLINICAL TRIALS FOR ACE INHIBITORS 56
TABLE 26 CLINICAL TRIALS FOR PROTON PUMP INHIBITORS 57
NEW DRUGS IN CLINICAL TRIALS 58
TABLE 27 NEW ENZYME INHIBITORS IN CLINICAL TRIALS 58
CHAPTER SEVEN: GLOBAL MARKETS 59
MARKET ANALYSIS 59
TABLE 28 GLOBAL MARKET FOR ENZYME INHIBITORS, THROUGH
2016 ($ MILLIONS) 60
FIGURE 1 GLOBAL MARKET FOR ENZYME INHIBITORS, 2009-2016
($ MILLIONS) 61
PROTON PUMP INHIBITORS 61
Market Overview 62
Market Revenue 63
TABLE 29 GLOBAL MARKET FOR PROTON PUMP INHIBITORS,
THROUGH 2016 ($ MILLIONS) 64
FIGURE 2 GLOBAL MARKET FOR PROTON PUMP INHIBITORS,
2009-2016 ($ MILLIONS) 64
PROTEASE INHIBITORS 64
Market Overview 65
Market Revenue 66
TABLE 30 GLOBAL MARKET FOR PROTEASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 67
FIGURE 3 GLOBAL MARKET FOR PROTEASE INHIBITORS, 2009-
2016 ($ MILLIONS) 67
REVERSE TRANSCRIPTASE INHIBITORS 67
Market Overview 68
Market Overview (Continued) 69
Market Revenue 70
TABLE 31 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 70
FIGURE 4 GLOBAL MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, 2009-2016 ($ MILLIONS) 71
KINASE INHIBITORS 71
Market Overview 72
Market Overview (Continued) 73
Market Revenue 74
TABLE 32 GLOBAL MARKET FOR KINASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 74
FIGURE 5 GLOBAL MARKET FOR KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 75
STATINS 75
Market Overview 76
Market Revenue 77
TABLE 33 GLOBAL MARKET FOR STATINS, THROUGH 2016 ($
MILLIONS) 78
FIGURE 6 GLOBAL MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 78
AROMATASE INHIBITORS 78
Market Overview 79
Market Revenue 80
TABLE 34 GLOBAL MARKET FOR AROMATASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 80
FIGURE 7 GLOBAL MARKET FOR AROMATASE INHIBITORS, 2009-
2016 ($ MILLIONS) 81
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 81
Market Overview 82
Market Revenue 83
TABLE 35 GLOBAL MARKET FOR PDE5 INHIBITORS, THROUGH
2016 ($ MILLIONS) 83
FIGURE 8 GLOBAL MARKET FOR PDE5 INHIBITORS, 2009-2016 ($
MILLIONS) 84
NEURAMINIDASE INHIBITORS 84
Market Overview 85
Market Revenue 85
TABLE 36 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 86
FIGURE 9 GLOBAL MARKET FOR NEURAMINIDASE INHIBITORS,
2009-2016 ($ MILLIONS) 86
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 86
Market Overview 87
Market Revenue 88
TABLE 37 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2016
($ MILLIONS) 88
FIGURE 10 GLOBAL MARKET FOR ACE INHIBITORS, 2009-2016 ($
MILLIONS) 89
MARKET SHARES 89
TABLE 38 PROTON PUMP INHIBITOR MARKET SHARES BY
REGION, 2010 (%) 89
FIGURE 11 PROTON PUMP INHIBITOR MARKET SHARES BY
REGION, 2010 (%) 90
TABLE 39 PROTEASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 90
FIGURE 12 PROTEASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 91
TABLE 40 REVERSE TRANSCRIPTASE INHIBITOR MARKET
SHARES BY REGION, 2010 (%) 91
FIGURE 13 REVERSE TRANSCRIPTASE INHIBITOR MARKET
SHARES BY REGION, 2010 (%) 92
TABLE 41 KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 92
FIGURE 14 KINASE INHIBITOR MARKET SHARES BY REGION, 2010
(%) 93
TABLE 42 STATINS INHIBITOR MARKET SHARES BY REGION, 2010
(%) 93
FIGURE 15 STATINS INHIBITOR MARKET SHARES BY REGION,
2010 (%) 94
TABLE 43 AROMATASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 94
FIGURE 16 AROMATASE INHIBITOR MARKET SHARES BY REGION,
2010 (%) 95
TABLE 44 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010 (%) 95
FIGURE 17 PDE5 INHIBITOR MARKET SHARES BY REGION, 2010
(%) 96
TABLE 45 NEURAMINIDASE INHIBITOR MARKET SHARES BY
REGION, 2010 (%) 96
FIGURE 18 NEURAMINIDASE INHIBITOR MARKET SHARES BY
REGION, 2010 (%) 97
TABLE 46 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 97
FIGURE 19 ACE INHIBITOR MARKET SHARES BY REGION, 2010 (%) 98
MARKET BY APPLICATIONS 98
TABLE 47 GLOBAL ENZYME INHIBITORS MARKET BY
THERAPEUTIC CATEGORIES/ DISEASE SECTORS, THROUGH
2016 ($ MILLIONS) 99
FIGURE 20 GLOBAL ENZYME INHIBITORS MARKET BY
THERAPEUTIC CATEGORIES/ DISEASE SECTORS, 2009-2016 ($
MILLIONS) 100
CARDIOVASCULAR (CV) DISEASE 100
Cardiovascular (CV) Disease (Continued) 101
TABLE 48 GLOBAL MARKET FOR ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 102
FIGURE 21 GLOBAL MARKET OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 103
GASTROINTESTINAL DISORDERS 103
TABLE 49 GLOBAL MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 104
FIGURE 22 GLOBAL MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 105
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 105
Acquired Immunodeficiency … (Continued) 106
TABLE 50 GLOBAL MARKET OF ENZYME INHIBITORS IN
HIV/AIDS, THROUGH 2016 ($ MILLIONS) 107
FIGURE 23 GLOBAL MARKET OF ENZYME INHIBITORS IN
HIV/AIDS, 2009-2016 ($ MILLIONS) 107
HEPATITIS 108
TABLE 51 GLOBAL MARKET OF ENZYME INHIBITORS IN
HEPATITIS, THROUGH 2016 ($ MILLIONS) 109
FIGURE 24 GLOBAL MARKET OF ENZYME INHIBITORS IN
HEPATITIS, 2009-2016 ($ MILLIONS) 109
CANCER 110
Cancer (Continued) 111
TABLE 52 GLOBAL MARKET OF ENZYME INHIBITORS IN VARIOUS
CANCERS, THROUGH 2016 ($ MILLIONS) 112
FIGURE 25 GLOBAL MARKET OF ENZYME INHIBITORS IN
VARIOUS CANCERS, 2009-2016 ($ MILLIONS) 113
ERECTILE DYSFUNCTION (ED) 113
TABLE 53 GLOBAL MARKET OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 114
FIGURE 26 GLOBAL MARKET OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 115
OTHERS 115
TABLE 54 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER
SECTORS, THROUGH 2016 ($ MILLIONS) 116
FIGURE 27 GLOBAL MARKET OF ENZYME INHIBITORS IN OTHER
SECTORS, 2009-2016 ($ MILLIONS) 117
GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY
APPLICATION 117
TABLE 55 GLOBAL MARKET SHARE OF ENZYME INHIBITORS BY
APPLICATION, 2010 (%) 118
FIGURE 28 GLOBAL MARKET SHARE OF TECHNICAL ENZYMES,
2010 (%) 118
CHAPTER EIGHT: MARKETS IN THE UNITED STATES 119
MARKET ANALYSIS 119
TABLE 56 U S MARKET FOR ENZYME INHIBITORS, THROUGH
2016 ($ MILLIONS) 120
FIGURE 29 U S MARKET FOR ENZYME INHIBITORS, 2009-2016 ($
MILLIONS) 121
PROTON PUMP INHIBITORS (PPI) 121
Market Overview 121
Market Overview (Continued) 122
Market Revenue 123
TABLE 57 U S MARKET FOR PROTON PUMP INHIBITORS,
THROUGH 2016 ($ MILLIONS) 123
FIGURE 30 U S MARKET FOR PROTON PUMP INHIBITORS, 2009-
2016 ($ MILLIONS) 124
PROTEASE INHIBITORS 124
Market Overview 125
Market Revenue 126
TABLE 58 U S MARKET FOR PROTEASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 126
FIGURE 31 U S MARKET FOR PROTEASE INHIBITORS, 2009-2016 ($
MILLIONS) 127
REVERSE TRANSCRIPTASE INHIBITORS 127
Market Overview 127
Market Overview (Continued) 128
Market Revenue 129
TABLE 59 U S MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 129
FIGURE 32 U S MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, 2009-2016 ($ MILLIONS) 129
KINASE INHIBITORS 130
Market Overview 130
Market Overview (Continued) 131
Market Revenue 132
TABLE 60 U S MARKET FOR KINASE INHIBITORS, THROUGH 2016
($ MILLIONS) 132
FIGURE 33 U S MARKET FOR KINASE INHIBITORS, 2009-2016 ($
MILLIONS) 132
STATINS 133
Market Overview 133
Market Overview (Continued) 134
Market Revenue 135
TABLE 61 U S MARKET FOR STATINS, THROUGH 2016 ($
MILLIONS) 135
FIGURE 34 U S MARKET FOR STATINS, 2009-2016 ($ MILLIONS) 136
AROMATASE INHIBITORS 136
Market Overview 137
Market Revenue 137
TABLE 62 U S MARKET FOR AROMATASE INHIBITORS, THROUGH
2016 ($ MILLIONS) 138
FIGURE 35 U S MARKET FOR AROMATASE INHIBITORS, 2009-2016
($ MILLIONS) 138
PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS 138
Market Overview 139
Market Revenue 140
TABLE 63 U S MARKET FOR PDE5 INHIBITORS, THROUGH 2016 ($
MILLIONS) 140
FIGURE 36 U S MARKET FOR PDE5 INHIBITORS, 2009-2016 ($
MILLIONS) 140
NEURAMINIDASE INHIBITORS 141
Market Overview 141
Market Revenue 141
TABLE 64 U S MARKET FOR NEURAMINIDASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 142
FIGURE 37 U S MARKET FOR NEURAMINIDASE INHIBITORS, 2009-
2016 ($ MILLIONS) 142
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 142
Market Overview 143
Market Revenue 144
TABLE 65 U S MARKET FOR ACE INHIBITORS, THROUGH 2016 ($
MILLIONS) 145
FIGURE 38 U S MARKET FOR ACE INHIBITORS, 2009-2016 ($
MILLIONS) 145
MARKET SHARES OF INDUSTRY LEADERS IN THE UNITED
STATES 145
PROTON PUMP INHIBITORS 145
TABLE 66 U S MARKET SHARES OF PROTON PUMP INHIBITOR
MANUFACTURERS, 2010 (%) 146
FIGURE 39 U S MARKET SHARES OF PROTON PUMP INHIBITOR
MANUFACTURERS, 2010 (%) 146
PROTEASE INHIBITORS 147
TABLE 67 U S MARKET SHARES OF PROTEASE INHIBITOR
MANUFACTURERS, 2010 (%) 147
FIGURE 40 U S MARKET SHARES OF PROTEASE INHIBITORS
MANUFACTURERS, 2010 (%) 147
KINASE INHIBITORS 148
TABLE 68 U S MARKET SHARES OF KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 148
FIGURE 41 U S MARKET SHARES OF KINASE INHIBITORS
MANUFACTURERS, 2010 (%) 148
STATINS 149
TABLE 69 U S MARKET SHARES OF STATINS MANUFACTURERS,
2010 (%) 149
FIGURE 42 U S MARKET SHARES OF STATINS MANUFACTURERS,
2010 (%) 149
AROMATASE INHIBITORS 150
TABLE 70 U S MARKET SHARES OF AROMATASE INHIBITOR
MANUFACTURERS, 2010 (%) 150
FIGURE 43 U S MARKET SHARES OF AROMATASE INHIBITOR
MANUFACTURERS, 2010 (%) 150
REVERSE TRANSCRIPTASE INHIBITORS 151
TABLE 71 U S MARKET SHARES OF REVERSE TRANSCRIPTASE
INHIBITOR MANUFACTURERS, 2010 (%) 151
FIGURE 44 U S MARKET SHARES OF REVERSE TRANSCRIPTASE
INHIBITOR MANUFACTURERS, 2010 (%) 152
PDE5 INHIBITORS 152
TABLE 72 U S MARKET SHARES OF PDE5 INHIBITOR
MANUFACTURERS, 2010 (%) 152
FIGURE 45 U S MARKET SHARES OF PDE5 MANUFACTURERS,
2010 (%) 153
NEURAMINIDASE INHIBITORS 153
TABLE 73 U S MARKET SHARES OF NEURAMINIDASE INHIBITOR
MANUFACTURERS, 2010 (%) 153
FIGURE 46 U S MARKET SHARES OF NEURAMINIDASE
MANUFACTURERS, 2010 (%) 154
ACE INHIBITORS 154
TABLE 74 U S MARKET SHARES OF ACE INHIBITOR
MANUFACTURERS, 2010 (%) 154
FIGURE 47 U S MARKET SHARES OF ACE MANUFACTURERS, 2010
(%) 155
MARKET BY APPLICATIONS 155
TABLE 75 U S ENZYME INHIBITORS MARKET BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS, THROUGH 2016 ($ MILLIONS) 156
FIGURE 48 U S MARKET INHIBITORS MARKET BY THERAPEUTIC
CATEGORIES/DISEASE SECTORS, 2009-2016 ($ MILLIONS) 156
CARDIOVASCULAR (CV) DISEASES 157
Cardiovascular (CV) Diseases (Continued) 158
TABLE 76 U S MARKET OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 159
FIGURE 49 U S MARKET OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 159
GASTROINTESTINAL DISORDERS 160
TABLE 77 U S MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 160
FIGURE 50 U S MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 161
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 161
TABLE 78 U S MARKET OF ENZYME INHIBITORS IN HIV/AIDS,
THROUGH 2016 ($ MILLIONS) 162
FIGURE 51 U S MARKET OF ENZYME INHIBITORS IN HIV/AIDS,
2009-2016 ($ MILLIONS) 163
HEPATITIS 163
Hepatitis (Continued) 164
TABLE 79 U S MARKET OF ENZYME INHIBITORS IN HEPATITIS,
THROUGH 2016 ($ MILLIONS) 165
FIGURE 52 U S MARKET OF ENZYME INHIBITORS IN HEPATITIS,
2009-2016 ($ MILLIONS) 165
CANCER 166
Cancer (Continued) 167
TABLE 80 U S MARKET OF ENZYME INHIBITORS IN VARIOUS
CANCER, THROUGH 2016 ($ MILLIONS) 168
FIGURE 53 U S MARKET OF ENZYME INHIBITORS IN VARIOUS
CANCER, 2009-2016 ($ MILLIONS) 168
ERECTILE DYSFUNCTION 168
TABLE 81 U S MARKET OF ENZYME INHIBITORS IN ERECTILE
DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 169
FIGURE 54 U S MARKET OF ENZYME INHIBITORS IN ERECTILE
DYSFUNCTION, 2009-2016 ($ MILLIONS) 170
OTHERS 170
TABLE 82 U S MARKET OF ENZYME INHIBITORS IN OTHER
SECTORS, THROUGH 2016 ($ MILLIONS) 171
FIGURE 55 U S MARKET OF ENZYME INHIBITORS IN OTHER
SECTORS, 2009-2016 ($ MILLIONS) 172
CHAPTER NINE: MARKETS IN EUROPE 173
MARKET ANALYSIS 173
TABLE 83 EUROPEAN MARKET FOR ENZYME INHIBITORS,
THROUGH 2016 ($ MILLIONS) 174
FIGURE 56 EUROPEAN MARKET FOR ENZYME INHIBITORS, 2009-
2016 ($ MILLIONS) 175
PROTON PUMP INHIBITORS 175
Market Overview 176
Market Revenue 177
TABLE 84 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS,
THROUGH 2016 ($ MILLIONS) 178
FIGURE 57 EUROPEAN MARKET FOR PROTON PUMP INHIBITORS,
2009-2016 ($ MILLIONS) 178
PROTEASE INHIBITORS 178
Market Overview 179
Market Revenue 180
TABLE 85 EUROPEAN MARKET FOR PROTEASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 180
FIGURE 58 EUROPEAN MARKET FOR PROTEASE INHIBITORS,
2009-2016 ($ MILLIONS) 181
REVERSE TRANSCRIPTASE INHIBITORS 181
Market Overview 181
Market Revenue 182
TABLE 86 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 183
FIGURE 59 EUROPEAN MARKET FOR REVERSE TRANSCRIPTASE
INHIBITORS, 2009-2016 ($ MILLIONS) 183
KINASE INHIBITORS 184
Market Overview 184
Market Overview (Continued) 185
Market Revenue 186
TABLE 87 EUROPEAN MARKET FOR KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 186
FIGURE 60 EUROPEAN MARKET FOR KINASE INHIBITORS, 2009-
2016 ($ MILLIONS) 186
STATINS 187
Market Overview 187
Market Revenue 188
TABLE 88 EUROPEAN MARKET FOR STATINS, THROUGH 2016 ($
MILLIONS) 189
FIGURE 61 EUROPEAN MARKET FOR STATINS, 2009-2016 ($
MILLIONS) 189
AROMATASE INHIBITORS 189
Market Overview 190
Market Revenue 191
TABLE 89 EUROPEAN MARKET FOR AROMATASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 191
FIGURE 62 EUROPEAN MARKET FOR AROMATASE INHIBITORS,
2009-2016 ($ MILLIONS) 191
PDE5 INHIBITORS 192
Market Overview 192
Market Revenue 192
TABLE 90 EUROPEAN MARKET FOR PDE5 INHIBITORS, THROUGH
2016 ($ MILLIONS) 193
FIGURE 63 EUROPEAN MARKET FOR PDE5 INHIBITORS,
THROUGH 2016 ($ MILLIONS) 193
NEURAMINIDASE INHIBITORS 194
Market Overview 195
Market Revenue 195
TABLE 91 EUROPEAN MARKET FOR NEURAMINIDASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 195
FIGURE 64 EUROPEAN MARKET FOR NEURAMINIDASE
INHIBITORS, 2009-2016 ($ MILLIONS) 196
ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS 196
Market Overview 196
Market Revenue 197
TABLE 92 EUROPEAN MARKET FOR ACE INHIBITORS, THROUGH
2016 ($ MILLIONS) 197
FIGURE 65 EUROPEAN MARKET FOR ACE INHIBITORS, 2009-2016
($ MILLIONS) 198
MARKET SHARES OF INDUSTRY LEADERS IN EUROPE 198
PROTON PUMP INHIBITORS 198
TABLE 93 EUROPEAN MARKET SHARES OF PROTON PUMP
INHIBITOR MANUFACTURERS, 2010 (%) 199
FIGURE 66 EUROPEAN MARKET SHARES OF PROTON PUMP
INHIBITOR MANUFACTURERS, 2010 (%) 199
PROTEASE INHIBITORS 200
TABLE 94 EUROPEAN MARKET SHARES OF PROTEASE INHIBITOR
MANUFACTURERS, 2010 (%) 200
FIGURE 67 EUROPEAN MARKET SHARES OF PROTEASE
INHIBITORS MANUFACTURERS, 2010 (%) 200
KINASE INHIBITORS 201
TABLE 95 EUROPEAN MARKET SHARES OF KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 201
FIGURE 68 EUROPEAN MARKET SHARES OF KINASE INHIBITORS
MANUFACTURERS, 2010 (%) 202
STATINS 202
TABLE 96 EUROPEAN MARKET SHARES OF STATINS
MANUFACTURERS, 2010 (%) 203
FIGURE 69 EUROPEAN MARKET SHARES OF STATINS
MANUFACTURERS, 2010 (%) 203
AROMATASE INHIBITORS 203
TABLE 97 EUROPEAN MARKET SHARES OF AROMATASE
INHIBITOR MANUFACTURERS, 2010 (%) 204
FIGURE 70 EUROPEAN MARKET SHARES OF AROMATASE
INHIBITOR MANUFACTURERS, 2010 (%) 204
REVERSE TRANSCRIPTASE INHIBITORS 204
TABLE 98 EUROPEAN MARKET SHARES OF REVERSE
TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%) 205
FIGURE 71 EUROPEAN MARKET SHARES OF REVERSE
TRANSCRIPTASE MANUFACTURERS, 2010 (%) 205
PDE5 INHIBITORS 205
TABLE 99 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR
MANUFACTURERS, 2010 (%) 206
FIGURE 72 EUROPEAN MARKET SHARES OF PDE5 INHIBITOR
MANUFACTURERS, 2010 (%) 206
NEURAMINIDASE INHIBITORS 206
TABLE 100 EUROPEAN MARKET SHARES OF NEURAMINIDASE
INHIBITOR MANUFACTURERS, 2010 (%) 207
FIGURE 73 EUROPEAN MARKET SHARES OF NEURAMINIDASE
INHIBITOR MANUFACTURERS, 2010 (%) 207
ACE INHIBITORS 207
TABLE 101 EUROPEAN MARKET SHARES OF ACE INHIBITOR
MANUFACTURERS, 2010 (%) 208
FIGURE 74 EUROPEAN MARKET SHARES OF ACE INHIBITOR
MANUFACTURERS, 2010 (%) 208
MARKET BY APPLICATIONS 208
TABLE 102 EUROPEAN ENZYME INHIBITORS MARKET BY
THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH
2016 ($ MILLIONS) 209
FIGURE 75 EUROPEAN ENZYME INHIBITORS MARKET BY
THERAPEUTIC CATEGORIES/DISEASE SECTORS, 2009-2016 ($
MILLIONS) 210
CARDIOVASCULAR (CV) DISEASES 210
Cardiovascular (CV) Diseases 211
TABLE 103 EUROPEAN MARKET OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, THROUGH 2016 ($ MILLIONS) 212
FIGURE 76 EUROPEAN MARKET OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASE, 2009-2016 ($ MILLIONS) 212
GASTROINTESTINAL DISORDERS 213
TABLE 104 EUROPEAN MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, THROUGH 2016 ($ MILLIONS) 214
FIGURE 77 EUROPEAN MARKET OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASE, 2009-2016 ($ MILLIONS) 214
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 215
TABLE 105 EUROPEAN MARKET OF ENZYME INHIBITORS IN
HIV/AIDS, THROUGH 2016 ($ MILLIONS) 216
FIGURE 78 EUROPEAN MARKET OF ENZYME INHIBITORS IN
HIV/AIDS, 2009-2016 ($ MILLIONS) 216
CANCER 216
Cancer (Continued) 217
TABLE 106 EUROPEAN MARKET OF ENZYME INHIBITORS IN
VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 218
FIGURE 79 EUROPEAN MARKET OF ENZYME INHIBITORS IN
CANCER, 2009-2016 ($ MILLIONS) 219
HEPATITIS 219
TABLE 107 EUROPEAN MARKET OF ENZYME INHIBITORS IN
HEPATITIS, THROUGH 2016 ($ MILLIONS) 220
FIGURE 80 EUROPEAN MARKET OF ENZYME INHIBITORS IN
HEPATITIS, 2009-2016 ($ MILLIONS) 221
ERECTILE DYSFUNCTION 221
TABLE 108 EUROPEAN MARKET OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 222
FIGURE 81 EUROPEAN MARKET OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 222
OTHER DISEASES 222
TABLE 109 EUROPEAN MARKET OF ENZYME INHIBITORS IN
OTHER DISEASES, THROUGH 2016 ($ MILLIONS) 223
FIGURE 82 EUROPEAN MARKET OF ENZYME INHIBITORS IN
OTHER DISEASES, 2009-2016 ($ MILLIONS) 224
CHAPTER TEN: EMERGING MARKETS 225
MARKET ANALYSIS 225
MARKET ANALYSIS (CONTINUED) 226
TABLE 110 EMERGING MARKETS FOR ENZYME INHIBITORS,
THROUGH 2016 ($ MILLIONS) 227
FIGURE 83 EMERGING MARKET FOR ENZYME INHIBITORS, 2009-
2016 ($ MILLIONS) 227
PROTON PUMP INHIBITORS 228
Market Overview 228
Market Revenue 229
TABLE 111 EMERGING MARKETS FOR PROTON PUMP
INHIBITORS, THROUGH 2016 ($ MILLIONS) 229
FIGURE 84 EMERGING MARKETS FOR PROTON PUMP
INHIBITORS, 2009-2016 ($ MILLIONS) 230
PROTEASE INHIBITORS 230
Market Overview 231
Market Revenue 231
TABLE 112 EMERGING MARKETS FOR PROTEASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 232
FIGURE 85 EMERGING MARKETS FOR PROTEASE INHIBITORS,
2009-2016 ($ MILLIONS) 232
REVERSE TRANSCRIPTASE INHIBITORS 232
Market Overview 233
Market Revenue 234
TABLE 113 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 235
FIGURE 86 EMERGING MARKETS FOR REVERSE TRANSCRIPTASE
INHIBITORS, 2009-2016 ($ MILLIONS) 235
KINASE INHIBITORS 235
Market Overview 236
Market Revenue 237
TABLE 114 EMERGING MARKETS FOR KINASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 237
FIGURE 87 EMERGING MARKETS FOR KINASE INHIBITORS, 2009-
2016 ($ MILLIONS) 238
STATINS 238
Market Overview 238
Market Overview (Continued) 239
Market Revenue 240
TABLE 115 EMERGING MARKETS FOR STATINS, THROUGH 2016 ($
MILLIONS) 240
FIGURE 88 EMERGING MARKETS FOR STATINS, 2009-2016 ($
MILLIONS) 241
AROMATASE INHIBITORS 241
Market Overview 241
Market Revenue 242
TABLE 116 EMERGING MARKETS FOR AROMATASE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 242
FIGURE 89 EMERGING MARKETS FOR AROMATASE INHIBITORS,
2009-2016 ($ MILLIONS) 242
PDE5 INHIBITORS 243
Market Overview 243
Market Revenue 243
TABLE 117 EMERGING MARKETS FOR PDE5 INHIBITORS,
THROUGH 2016 ($ MILLIONS) 244
FIGURE 90 EMERGING MARKETS FOR PDE5 INHIBITORS, 2009-
2016 ($ MILLIONS) 244
NEURAMINIDASE INHIBITORS 244
Market Overview 245
Market Revenue 245
TABLE 118 EMERGING MARKETS FOR NEURAMINIDASE
INHIBITORS, THROUGH 2016 ($ MILLIONS) 246
FIGURE 91 EMERGING MARKETS FOR NEURAMINIDASE
INHIBITORS, 2009-2016 ($ MILLIONS) 246
ACE INHIBITORS 246
Market Overview 247
Market Revenue 247
TABLE 119 EMERGING MARKETS FOR ACE INHIBITORS,
THROUGH 2016 ($ MILLIONS) 248
FIGURE 92 EMERGING MARKETS FOR ACE INHIBITORS, 2009-2016
($ MILLIONS) 248
MARKET SHARES OF INDUSTRY LEADERS IN EMERGING
MARKETS 248
PROTON PUMP INHIBITORS 248
TABLE 120 EMERGING MARKET SHARES OF PROTON PUMP
INHIBITOR MANUFACTURERS, 2010 (%) 249
FIGURE 93 EMERGING MARKET SHARES OF PROTON PUMP
INHIBITOR MANUFACTURERS, 2010 (%) 249
PROTEASE INHIBITORS 249
TABLE 121 EMERGING MARKET SHARES OF PROTEASE
INHIBITOR MANUFACTURERS, 2010 (%) 250
FIGURE 94 EMERGING MARKETS SHARES OF PROTEASE
INHIBITORS MANUFACTURERS, 2010 (%) 250
KINASE INHIBITORS 251
TABLE 122 EMERGING MARKET SHARES OF KINASE INHIBITOR
MANUFACTURERS, 2010 (%) 251
FIGURE 95 EMERGING MARKET SHARES OF KINASE INHIBITORS
MANUACTURERS, 2010 (%) 252
STATINS 252
TABLE 123 EMERGING MARKET SHARES OF STATINS
MANUFACTURERS, 2010 (%) 252
FIGURE 96 EMERGING MARKETS SHARES OF STATINS
MANUFACTURERS, 2010 (%) 253
AROMATASE INHIBITORS 253
TABLE 124 EMERGING MARKET SHARES OF AROMATASE
INHIBITOR, 2010 (%) 253
FIGURE 97 EMERGING MARKET SHARES OF AROMATASE
INHIBITOR MANUFACTURERS, 2010 (%) 254
REVERSE TRANSCRIPTASE INHIBITORS 254
TABLE 125 EMERGING MARKET SHARES OF REVERSE
TRANSCRIPTASE INHIBITOR MANUFACTURERS, 2010 (%) 254
FIGURE 98 EMERGING MARKET SHARES OF REVERSE
TRANSCRIPTASE MANUFACTURERS, 2010 (%) 255
PDE5 INHIBITORS 255
TABLE 126 EMERGING MARKET SHARES OF PDE5 INHIBITOR
MANUFACTURERS, 2010 (%) 255
FIGURE 99 EMERGING MARKET SHARES OF PED5
MANUFACTURERS, 2010 (%) 256
NEURAMINIDASE INHIBITORS 256
TABLE 127 EMERGING MARKET SHARES OF NEURAMINIDASE
INHIBITOR MANUFACTURERS, 2010 (%) 256
FIGURE 100 EMERGING MARKET SHARES OF NEURAMINIDASE
MANUFACTURERS, 2010 (%) 257
ACE INHIBITORS 257
TABLE 128 EMERGING MARKET SHARES OF ACE INHIBITOR
MANUFACTURERS, 2010 (%) 257
FIGURE 101 EMERGING MARKET SHARES OF ACE INHIBITOR
MANUFACTURERS, 2010 (%) 258
MARKET BY APPLICATIONS 258
TABLE 129 EMERGING MARKETS IN ENZYME INHIBITORS BY
THERAPEUTIC CATEGORIES/DISEASE SECTORS, THROUGH
2016 ($ MILLIONS) 259
FIGURE 102 EMERGING MARKETS IN ENZYME INHIBITORS BY
THERAPEUTIC CATEGORIES/DISEASE SECTORS ($ MILLIONS) 259
CARDIOVASCULAR (CV) DISEASE 260
Cardiovascular (CV) Disease (Continued) 261
TABLE 130 EMERGING MARKETS OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASES, THROUGH 2016 ($ MILLIONS) 262
FIGURE 103 EMERGING MARKETS OF ENZYME INHIBITORS IN
CARDIOVASCULAR DISEASES, 2009-2016 ($ MILLIONS) 262
GASTROINTESTINAL DISORDERS 263
TABLE 131 EMERGING MARKETS OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASES, THROUGH 2016 ($ MILLIONS) 263
FIGURE 104 EMERGING MARKETS OF ENZYME INHIBITORS IN
GASTROINTESTINAL DISEASES, 2009-2016 ($ MILLIONS) 264
ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 264
TABLE 132 EMERGING MARKETS OF ENZYME INHIBITORS IN
HIV/AIDS, THROUGH 2016 ($ MILLIONS) 265
FIGURE 105 EMERGING MARKETS OF ENZYME INHIBITORS IN
HIV/AIDS, 2009-2016 ($ MILLIONS) 266
HEPATITIS 266
TABLE 133 EMERGING MARKETS OF ENZYME INHIBITORS IN
HEPATITIS, THROUGH 2016 ($ MILLIONS) 267
FIGURE 106 EMERGING MARKETS OF ENZYME INHIBITORS IN
HEPATITIS, 2009-2016 ($ MILLIONS) 268
CANCER 268
TABLE 134 EMERGING MARKETS OF ENZYME INHIBITORS IN
VARIOUS CANCERS, THROUGH 2016 ($ MILLIONS) 269
FIGURE 107 EMERGING MARKETS OF ENZYME INHIBITORS IN
VARIOUS CANCERS, 2009-2016 ($ MILLIONS) 270
ERECTILE DYSFUNCTION (ED) 270
TABLE 135 EMERGING MARKETS OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, THROUGH 2016 ($ MILLIONS) 271
FIGURE 108 EMERGING MARKETS OF ENZYME INHIBITORS IN
ERECTILE DYSFUNCTION, 2009-2016 ($ MILLIONS) 271
OTHER DISEASES 271
TABLE 136 EMERGING MARKETS OF ENZYME INHIBITORS IN
OTHER DISEASES, THROUGH 2016 ($ MILLIONS) 272
FIGURE 109 EMERGING MARKETS OF ENZYME INHIBITORS IN
OTHER DISEASES, 2009-2016 ($ MILLIONS) 273
CHAPTER ELEVEN: PATENT ANALYSIS 274
PATENTS BY YEAR 274
TABLE 137 NUMBER OF SIGNIFICANT PATENTS BY YEAR, 2008-
2012 275
FIGURE 110 NUMBER OF PATENTS BY YEAR, 2008-2012 275
FIGURE 111 NUMBER OF PATENTS BY YEAR, 2008-2012 (%) 276
PATENTS BY TYPE 276
TABLE 138 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-
2012 277
FIGURE 112 PATENTS BY TYPE FOR ENZYME INHIBITORS, 2008-
2012 277
PATENTS BY COMPANY 278
TABLE 139 NUMBER OF U S PATENTS BY COMPANY FOR ENZYME
INHIBITORS, 2008-2012 278
TABLE 139 (CONTINUED) 279
PATENTS BY COUNTRY 280
TABLE 140 TOTAL NUMBER OF U S PATENTS BY COUNTRY FOR
ENZYME INHIBITORS, 2008-2012 280
FIGURE 113 TOTAL NUMBER OF U S PATENTS BY COUNTRY FOR
ENZYME INHIBITORS, 2008-2012 281
TABLE 141 PATENT SHARES BY COUNTRY FOR INDUSTRIAL
ENZYMES, 2008-2012 (%) 281
FIGURE 114 PATENT SHARES BY COUNTRY FOR ENZYME
INHIBITORS, 2008-2012 (%) 282
PATENTS BY ASSIGNEE 282
TABLE 142 PATENTS BY TYPE FOR INDUSTRIAL ENZYMES, 2008-
2012 282
FIGURE 115 PATENTS BY ASSIGNEE FOR INDUSTRIAL ENZYMES,
2008-2012 (%) 283
CHAPTER TWELVE: CURRENT SITUATION 284
MARKET CONDITIONS 284
UNITED STATES 284
EUROPE 284
EMERGING MARKETS 285
TRENDS AND ISSUES IN ENZYME INHIBITORS MARKET 285
COMPETITION 285
PATENT EXPIRATIONS 285
UPCOMING PATENT EXPIRATIONS/UPCOMING PATENT
CLIFF 286
PATENT CHALLENGES / LEGAL PROCEEDINGS 286
NEW INDICATIONS APPROVED 286
NEW DRUG APPROVALS 287
RX- TO- OTC SWITCH 287
INCREASING NUMBER OF BABY BOOMERS 288
MERGERS AND ACQUISITIONS AND ALLIANCES 288
DIRECT-TO-CONSUMER ADVERTISING 289
CHAPTER THIRTEEN: COMPANY PROFILES 290
ABBOTT LABORATORIES 290
AMGEN INC 290
ASTRAZENECA PLC 291
AUROBINDO PHARMA 291
BAYER HEALTHCARE PHARMACEUTICALS 292
BOEHRINGER INGELHEIM GMBH 292
BRISTOL-MYERS SQUIBB 293
CIPLA LTD 294
DR REDDY’S LABORATORIES LTD 294
EISAI INC 295
ELI LILLY and CO 295
ENDO PHARMACEUTICALS 296
GILEAD SCIENCES INC 297
GLAXOSMITHKLINE PLC 297
GLENMARK GENERICS LTD 298
HETERO DRUGS LTD 298
HOFFMAN-LA ROCHE LTD 299
INCYTE CORP 299
JOHNSON and JOHNSON 300
LUPIN PHARMACEUTICALS INC 301
MERCK and CO INC 301
MERCK SERONO SA 302
MYLAN LABORATORIES INC 303
MYLAN LABORATORIES LTD 303
NOVARTIS AG 304
OSI PHARMACEUTICALS LLC 305
PAR PHARMACEUTICAL COMPANIES INC 305
PFIZER INC 306
RANBAXY LABORATORIES LTD 307
ROXANE LABORATORIES LTD 307
SANDOZ 308
SANOFI-AVENTIS 308
SANTARUS INC 309
SUN PHARMACEUTICALS 310
TAKEDA PHARMACEUTICAL CO LTD 310
TEVA PHARMACEUTICAL INDUSTRIES LTD 311
VERTEX PHARMACEUTICALS 311
VIIV HEALTHCARE

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023 Summary The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected ...

Antibiotics: Technologies and Global Markets

Antibiotics: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Identify the major market trends and the factors driving or inhibiting the growth of the global pharmaceutical antibiotics market and its various submarkets. - Learn about developments ...

Antifungal Drugs : Technologies and Global Markets

Antifungal Drugs : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This report aims to determine the current status of the global human antifungal market and assess its growth potential over the five-year period from 2013 through 2018. It covers approved human therapeutics ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.